Dianabol vs Doxepin
Well Studied vs FDA Approved
avoid Mechanism-based · 60% Both Dianabol and Doxepin carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.
Molecular Data
Dianabol Doxepin
Weight 300.44 Da 279.38 Da
Half-life ~4-6 hours ~15 hours
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Tricyclic dibenzoxepin derivative (C19H21NO)
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Doxepin
01 FDA-approved specifically for sleep maintenance insomnia at ultra-low doses (3-6 mg as Silenor)
02 Highly selective H1 antihistamine at low doses, avoiding the side effects of traditional tricyclic antidepressants
03 Non-habit-forming with no dependence, tolerance, or abuse potential
04 No rebound insomnia upon discontinuation, unlike benzodiazepines and Z-drugs
05 Particularly effective for maintaining sleep in the latter half of the night, when many other sleep aids have worn off
06 Extremely well-tolerated side effect profile at ultra-low doses
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Doxepin
Morning drowsiness or grogginess (more common at the 6 mg dose; uncommon at 3 mg)
Dry mouth (mild at ultra-low doses, much less than at antidepressant doses)
Nausea
Upper respiratory tract infection (observed in clinical trials at rates similar to placebo)
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Known hypersensitivity to doxepin or other dibenzoxepines
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
Untreated narrow-angle glaucoma
Severe urinary retention
Severe hepatic impairment (doxepin is extensively hepatically metabolized)
Research Evidence
Dianabol Doxepin
Status Well Studied FDA Approved
References 5 studies 4 studies
Latest 2017 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.